on EURAZEO (EPA:RF)
Kurma Partners Sells ImCheck Therapeutics to Ipsen for Up to €1 Billion
Kurma Partners, under the Eurazeo group, announced the sale of ImCheck Therapeutics to pharmaceutical company Ipsen. The transaction is valued at €350 million, potentially reaching €1 billion with milestone payments. Founded in 2015, ImCheck specializes in developing immunotherapy antibodies targeting various cancers.
The deal showcases Kurma's successful strategy of backing promising biotech firms from inception to acquisition. Supported by scientific work from Professor Daniel Olive, ImCheck's lead program, ICT01, shows promise in treating acute myeloid leukemia. Kurma's model has previously succeeded with companies like Corlieve Therapeutics and Amolyt Pharma.
The acquisition is anticipated to close by Q1 2026. ImCheck's CEO, Pierre d'Epenoux, expressed enthusiasm about joining Ipsen to further innovate cancer treatments. This sale highlights Kurma's role in driving European biotech advancements.
R. E.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all EURAZEO news